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different forms  
of ATS use
Introduction 
Amphetamine-Type Stimulants (ATS) are the se-
cond most commonly used illicit drugs worldwi-
de as well as in Europe (1,2). In Europe, the hig-
hest last-year prevalence for amphetamine use 
among young adults aged 15-34 years is found in 
Germany (2.9%) and for MDMA in the Netherlands 
(6.9%) (1). Methamphetamine has been a main 
drug of use for over four decades in the Czech 
Republic, and increasing use has been reported 
in Cyprus, (eastern) Germany, Slovakia and Spain, 
as well as in parts of Northern Europe (3).
Long term ATS use can lead to physical (4,5), men-
tal (6) and social (7) harms, including (psychologi-
cal) dependence (8,9). Harms may include car-
diovascular complications, neurological damage, 
liver damage and intoxication (10) and memory 
impairment (11). Mental health issues, such as 
induced paranoia and psychosis (12), as well as 
sleep disorders, depressed mood and  persistent 
anxiety (13) are also reported by ATS users. Besi-
des, people who use ATS are more likely than tho-
se who use opioids to engage in risky sexual acti-
vities, increasing their risk for contracting various 
sexually transmitted infections (STIs) (7).  
No single intervention can address the variety of 
issues experienced by people who use ATS. Any 
comprehensive package needs to consider the 
specificity of different ATS substances and pat-
terns of use. Contextual variations, such as social, 
cultural, and legal aspects, also define the type 
and feasibility of interventions.
Despite the increasing use of ATS and the speci-
ficities related to these substances, most inter-
ventions directed to prevent, treat or reduce the 
harms of illicit drug use currently focus on (injec-
ted) opioids (14,15). Yet people who use ATS usu-
ally do not identify with (problematic) opioid use, 
often belong to different user networks and do 
not perceive opioid-focused services as relevant 
to them (16). They are likely to develop different 
trajectories of drug use, face different drug-rela-
ted harms, and have different needs than those 
using opioids, thus requiring specific or adapted 
services (17). 
This policy brief aims at contributing to the reduc-
tion of the harms of ATS use by describing diffe-
rent trajectories of ATS use and offering a set of 
evidence-based interventions for different groups 
of ATS users. The different ATS trajectories are ba-
sed on qualitative findings of large multinational 
research, the ATTUNE study, conducted between 
February and August 2017 in five European coun-
tries – the Netherlands, UK, Germany, Poland 
and the Czech Republic. The evidence-based 
interventions recommended in this brief are ba-
sed on a literature review. In this document, we 
combine both ATS trajectories and interventi-
ons from previous studies/programmes to pro-
pose tailor-made recommendations for peop-
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le who use ATS and those providing services to 
them. The following sections in this brief describe: 
1. The different types of ATS and the context 
of their use in Europe;
2. The various ATS use trajectories that ATTU-
NE study participants have experienced;
3. A set of evidence-based interventions to 
prevent, treat and reduce the harms cau-
sed by ATS use; and,
4. Recommendations for policymakers, 
practitioners and others working with 
drug-related services.
ATS types and use  
in Europe
Amphetamine-type substances (ATS) are a group 
composed of synthetic stimulants. All ATS have an 
amphetamine base, but each ATS type has spe-
cific characteristics and effects. Their occurrence 




Also called speed, amphetamine is a central 
nervous system stimulant, as are all other forms of 
ATS. Amphetamine generally comes in the form 
of a white or yellow powder but can also come 
in tablet form. It can generally be swallowed, 
snorted or injected.
Amphetamine is the most prevalent form of ATS 
used in Western and Central Europe. Since 2009, 
its use has been relatively stable in most countries 
of this region, except in Germany and the Nether-
lands which have reported an increase (2). Long-
term and injecting amphetamine use have, histo-
rically, been most evident in northern European 
countries (1). The European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) estimates 
that 12.3 million adults in the European Union (EU) 
(aged 15-64 years) have used amphetamines at 
least once in their lifetime (1).
 
Methamphetamine
Also called crystal meth, ice, crystal, meth, shabu 
or Tina. It is similar to amphetamine in its structu-
re but is more potent and has, in general, longer 
effects. It is available in the form of crystalline hy-
drochloride, formulated tablets, and powder (18) 
and it can be taken orally, intranasal, through in-
halation, smoked as a vapour or injected. 
The Czech Republic is the only country in Europe 
where methamphetamine has been a main drug 
of use for over four decades (19). Nevertheless, 
increasing use of the drug has also been repor-
ted in  countries such as Cyprus, (eastern) France, 
Germany, Slovakia, Spain and Turkey, as well as in 
parts of Northern Europe (3). Use of methamphe-
tamine is reported as rising especially among peo-
ple who practice chemsex (1).
 
Amphetamine-like NPS 
New Psychoactive Substances (NPS) can include 
stimulants, depressants and hallucinogen substan-
ces. Stimulants make up the biggest group (36%) 
of all NPS (2). Examples of amphetamine-like NPS 
include synthetic cathinones (such as mephe-
drone, methylone, methedrone, butylone, MDAI, 
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buphedrone, and flephedrone), 4-FA, 4-MA, MDA 
and PMA (20). These drugs can be administered 
orally, rectally, intramuscularly, intravenously, or 
by inhalation (21). Synthetic cathinones are the 
largest group of stimulant NPS reported to the EU 
early warning system (1). NPS are sometimes pre-
ferred by users to more traditional drugs due to 
their “legal” status. 
 
Amphetamine-type prescription drugs
Since the 1920s, amphetamine has been used as 
a legal prescription to treat asthma, depression, 
and to combat fatigue in soldiers during the World 
War II. Restrictions were enforced in the 1970s, al-
lowing amphetamine in certain medicines. Now-
adays, amphetamines and amphetamine deriva-
tives are used in the treatment of narcolepsy (a 
sleep disorder) and attention deficit hyperactivity 
disorder (ADHD) (3). Medical use of amphetami-
nes and amphetamine derivatives (such as Rital-
in) has increased steadily over the past decade, 
yet nonmedical use of these substances has also 
increased, especially among university students 
(22). Motives for nonmedical use of prescription 
stimulants generally include improved concentra-
tion and to perform better at university (23).
 
MDMA
Also known as ecstasy, MDMA is a popular recre-
ational drug particularly associated with nightlife 
and dance settings. MDMA is traditionally availa-
ble in pills but, since 2010, its forms have diversified 
to include high-purity powder and crystals, also 
commonly used in Europe. MDMA is usually inge-
sted orally and its use is relatively higher among 
younger people (2). In the past, MDMA has been 
used as a psychotherapeutic drug to improve 
communication and helping to achieve greater 
insights (24). Nowadays, the use of MDMA in a the-
rapeutic setting has been increasingly debated 
and studied (25–27).
An estimated 13.6 million people, or 4.1% of adults 
(aged 15-64 years) in the European Union have 
used MDMA at least once in their lifetime. In Eu-
rope, the prevalence of past-year use of ecstasy 
is higher in Western and Central Europe (0.8%) (2). 
The higher estimates are in the Netherlands whe-
re 6.9% of the adult population have ever used 
MDMA (1). Both the Netherlands and the United 
Kingdom reported a decreasing trend of MDMA 
use in the last year, while Germany has reported 
an increasing trend (2). 
 
ATS trajectories
The types of harms faced by people who use ATS 
can vary by the type of ATS substance, the con-
text whereby drug use takes place, and person-
al characteristics. These will also lead to different 
trajectories of ATS use. There are four key phases 
in drug use trajectories: initiation, continuation, in-
crease/relapse and decrease/abstinence (28). In 
each phase, individual, social and environmental 
influences may shape the entrance to, continu-
ation of, or exit from, the phase (28). The ATTUNE 
study aimed at mapping different trajectories and 
the factors influencing them through the targeting 
of six different groups of people who use(d) ATS:
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1. Currently dependent1 users (CDU);
2. Formerly dependent users (FDU);
3. Non-dependent current2 frequent3  
users (CNU);
4. Formerly frequent users (FFU);
5. Non-frequent users (NFU); and,
6. Exposed non-users (NU)4.
 
A total of 279 people who use(d) ATS were inter-
viewed in the Czech Republic, Germany, the Neth-
erlands, Poland and the UK. To better focus on ATS, 
people reporting to have an opioid dependence 
were excluded from the study. Only people of 18 
years of age and above were included. Each of 
the boxes below describe a fictitious person, rep-
resenting common stories of the different people 
within each ATS trajectory according to the expe-
riences reported by ATTUNE participants. 
1  Dependence on ATS was assessed using the severity of dependence scale (GOSSOP, et al., 1995)  
with the recommended cut-off for ATS of ≥ 4 points (Bruno, et al., 2009).
2  Current use referred to ATS use in the past 12 months.
3  Frequent use was defined as > 10 consumption days in 12 months.
4  Exposure to ATS use was operationalised as having opportunities to take ATS due to being present when peers,  
partners, and/or family members were using ATS.
GROUP 1  
Currently dependent users (CDU)
Bob is 32 years old. He grew up in a small village 
with both his parents and his brother. His youth 
was quite average but he dropped out of school 
when he was 16 as he had difficulties with con-
centration and he preferred handing out with his 
peers. He lives with room-mates in a big city and 
since he lost his job in a convenience store some 
months ago, he has been on welfare. He uses 
amphetamine almost daily, usually by ‘bombing’ 
it after he wakes up. That kickstarts his day and 
gives him some energy and motivation to do his 
daily household chores. It also helps him to feel 
less depressed. He started using ATS when he was 
16. He first initiated ecstasy use in a club but, soon 
thereafter, discovered he preferred the effects 
that amphetamine gave him. As he partied more 
often with peers, his use increased from monthly 
to weekly rather fast, and in the first years of his 
ATS career, weekends of 3 days in a row partying 
and using drugs were common. Soon, his social 
network, including on-and-off romantic partners, 
consisted mainly of other frequent speed users, 
and that remained unchanged. They often use 
speed together, combined with large amounts 
of alcohol. Side effects of his speed use includes 
memory loss, troubles with his daily functioning 
and sleep problems. To sleep easier, he usually 
smokes cannabis before he goes to bed. Bob 
went into treatment once, mainly out of financial 
debts that he wanted to deal with. He managed 
to quit using speed for some time, but relapsed. 
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GROUP 2  
Formerly dependent users (FDU)
Carl came out of treatment for his speed and 
alcohol dependence a year ago. He is 33 years 
old and it was the third time he had been in 
treatment, yet this time he feels he succeeded 
better as it gave him new insights into his reasons 
for use. While it started recreationally when he 
was 18, generally at home with peers, he now 
recognises that his ATS use was also driven by 
the desire to forget his problems and as a way 
of coping with difficult situations and emotions 
in his life. His parents divorced when he was 15 
and the years beforehand were characterised 
by many fights. He didn’t see his father often 
between the age of 15 and 20 and entered 
the squat scene after finishing school. There he 
lived with many ATS users, including some who 
dealt drugs, and his use increased rapidly to 
(almost) daily. That negatively impacted his dai-
ly functioning in different areas such as social 
relationships and work; he experienced difficul-
ties getting out of bed, feelings of depression 
and sometimes paranoid. At a certain point he 
realised he had lost control, but his ATS-using en-
vironment made it difficult for him to decrease 
or quit using ATS, and his mental health went 
downhill. The turning point was when a friend 
of his suddenly died, making him realise that he 
wanted to change and feel better about him-
self. During the last treatment sessions, he made 
specific plans to reorganise his daily life, includ-
ing steps to move to his own place and change 
his social network. He has used ATS a few times 
in the past year and is not sure he will never use 
again, but no longer feels dependent on it.
GROUP 3  
Currently frequent non-dependent ATS users 
(CFU)
Mia is 29 years old and a true party animal. She 
is always game for a fun night and known for 
being the last to leave a party. Her perfect night 
combines friends with music, dancing and meet-
ing new people. She likes a drink, but prefers ATS 
to make a night out even better. Depending 
on the context, she commonly starts the night 
with ecstasy, which she takes to feel energetic, 
talkative and happy. During the night, she takes 
some speed or cocaine to refresh her energy 
and ends with cannabis to come down. Since 
she tried ATS for the first time when she was al-
most 19, she tries to stick to the informal rule 
of using not more than every 6 weeks, but not 
always successfully. Most of her friends also go 
out a lot and use ATS quite frequently. They take 
into account ‘suicide Tuesday’ by not planning 
much on that day, eating healthy and going to 
bed early after ATS use. She is a part-time stu-
dent and works three days a week in a café. She 
sometimes skips a class if her hangover is very 
bad. She tried Ritalin a few times to focus on a 
study assignment but it wasn’t her thing. She lives 
in a student house with 7 others and goes to her 
parents for the weekend once a month. While 
she is, and always has been, on good terms with 
them, they are not aware of her party lifestyle 
and she prefers to keep it that way. While she 
is quite open about her drug use and has men-
tioned it once, she doesn’t feel like it is some-
thing to share with her parents. 
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GROUP 4  
Formerly frequent non-dependent ATS users 
(FFU)
Adam is 32 years old. He lives with a partner 
and their 2-year-old son in a medium-sized city. 
He grew up as an only child and his parents 
divorced when he was 8 years old. He was 17 
when he initiated ATS use which was at a party 
with a friend who had used ecstasy several times 
before. His friend offered it to him, he was curi-
ous and took it. He had a great night dancing 
and socialising. Since then, his ATS use increased 
and, on average, he used ATS every six-to-eight 
weeks at parties and festivals, mainly ecstasy but 
sometimes also amphetamine and NPS. At one 
of those parties, he met his current partner and 
they also used ATS together. His use has varied a 
bit over the years, usually using more in summer 
than in winter. After finishing his studies, he found 
a job he liked and strived for promotion. Simulta-
neously, his use decreased slowly but steadily as 
he partied less often and more frequently associ-
ated with colleagues from work who happened 
to be non-ATS users. Also, the effects of ATS be-
gan to wear off and the side effects no longer 
outweighed the positive effects it used to bring 
him. Since his son was born, his lifestyle changed 
somewhat as it became more concentrated on 
his family. When meeting with his friends, he now 
usually likes to talk instead of dance together. 
He hasn’t used ATS since, and while he doesn’t 
want to pledge that he will never use it any-
more, he hasn’t felt the need to use again.
GROUP 5  
Non-frequent ATS users (currently and formerly) 
(NFU)
Tom works full-time as a social worker and is 31 
years old. He lives alone in a small city not far 
from his parents. In his leisure time he likes to play 
football, go to a café with friends and or just 
chill at home and watch tv series. When he was 
19, he and his best friend bought ecstasy from 
a dealer and, after searching for information on 
the internet, they tried it at home. He found the 
effects mediocre; but when, some years later, he 
took it again at a festival, he had a great time, 
feeling sociable, talkative and secure. Since 
then, he uses drugs irregularly, generally ecsta-
sy twice a year and magic mushrooms once a 
year. The effects of ATS are varying, sometimes 
positive but he also had some negative experi-
ences where he felt anxious, almost panicky and 
uncomfortable, waiting for the effects to dimin-
ish. In addition, he finds the side effects quite 
tough as he usually needs a week to get back 
on track, making it difficult to combine it with his 
job and responsibilities. Therefore, he keeps his 
drug use to special occasions. 
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GROUP 6  
Exposed non ATS users (NU)
Eva is a 29-year-old female. She grew up with 
loving parents and a younger sister in a village 
close to a big city. She was a fast learner and 
finished her studies some years ago. After that, 
she started working as a teacher. She lives on 
her own and is single. She spends her leisure time 
mainly by going out for dinner and drinks with 
her friends. She has both ATS-using and non-using 
friends. When clubbing, some of them use ATS 
and they have offered it to her several times to 
try. However, she’s never been interested, and 
while her peers usually seem to enjoy the effects, 
she refrains from it. She likes to stay in control and 
you never know how the effects will work out. For 
a year she dated a girl who used ATS every now-
and-then, but that didn’t work out. Eva drinks 
alcohol when going out, and while she has used 
cannabis periodically, she has never really been 
into drugs. While she never felt pressured to try 
ATS, she sometimes decides to not join her friends  
at a festival when she knows they will use ATS, or 
she makes sure there are other non-users she can 
hang out with.
Protective and risk factors of different 
phases
As one can see from the stories of Bob, Carl, Mia, 
Adam, Tom and Eva, not only the type of sub-
stance used is important to indicate if someone 
will become dependent, a frequent user, or only 
use occasionally. The life context, the surroundings 
and the personal characteristics are also crucial 
to define how someone will relate to a substance 
(29).  
From the stories above, we can see that a risk fac-
tor possibly leading to initiation of ATS use is hedo-
nism - curiosity, pleasure seeking or staying awake 
at a party - as in the case of Mia, for example. 
Risk factors leading to continuation of use include 
functional reasons (improving work/study/sexual 
performance); using for coping with difficulties or 
mental health problems; experiencing positive ef-
fects (alertness, connectedness and no hunger); 
and having friends or who (frequently) use ATS. 
Protective factors, on the other hand, can be the 
willingness to keep a clear mind, and fear of losing 
control, or of unpredictable effects, such as in the 
case of Tom or Eva (who never even tried). Experi-
encing negative effects can also prevent people 
in the initial phases from continuing or increasing 
use. 
In continuing or increasing phases of ATS use, risk 
factors can include the desire to preserve the 
positive effects of ATS and by frequenting set-
tings where ATS use is normalised (such as being 
involved in the party scene as with Mia); and 
having a network of friends who use ATS, as was 
the case for Carl. Becoming a more experienced 
user and being willing to experiment with multiple 
drugs - in general to counter or balance their ef-
fects, such as with Mia - is also a risk factor leading 
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to increased ATS use. Using ATS is also related to 
to coping with demands of everyday life, to lose 
weight or to feel more energetic. Engagement in 
chemsex practices also offers a higher risk of in-
creased ATS use, especially methamphetamine.   
Dependent phases of ATS use, such as in the ca-
ses of Bob and Carl, were observed mostly for me-
thamphetamine and amphetamine. Risk factors 
to become dependent on ATS use, as reported 
by ATTUNE participants, include having underlying 
mental health problems, such as Bob who nee-
ded to use to be able to start the day and feel 
less depressed. Having alcohol dependence was 
also a risk factor. A rapid increase in frequency of 
use, as in the case of Carl, led more frequently to 
a dependent pattern of use. Protective factors, 
both for dependent phases and increasing pha-
ses, included experiencing (other) side effects or 
health problems related to ATS use, such as Bob’s 
experiences of paranoia and depression. Incre-
asing life responsibilities and changing life priorities 
(such as having a family or a job, as with Adam) 
also acted as a protection, leading to decreasing 
or quitting use. 
 
Interventions for ATS use 
In the last decades, an increasing body of stu-
dies has analysed and proposed prevention, 
treatment and harm reduction interventions for 
people who use ATS. Researchers have studied, 
for instance,  substitution treatment for ATS (30), 
interventions to reduce the harms of MDMA use 
(31), and forms of preventing dependent use on 
different ATS substances (32). A few overviews of 
recommended interventions are also provided by 
different organisations in the harm reduction and 
drug policy field  (12, 33, 34, 77). 
Studies usually investigate the effectiveness of 
interventions for a specific substance, or form of 
administration. Less attention is paid to the phase 
of ATS use in which such interventions can be be-
neficial. This gap can be filled by combining the 
different ATS trajectories and experiences of use 
as found in the ATTUNE study with the scientific lite-
rature around interventions for ATS use. Below, evi-
dence-based interventions are described which 
can be beneficial to reduce the harms of ATS use 
in different phases of ATS consumption.
 
Evidence-based information 
Providing evidence-based information for ATS 
use(rs) about substances and their effects, and 
how to reduce the potential harms of its use, can 
be beneficial in several phases of ATS use. 
In the case of MDMA, for instance, important 
aspects to consider when choosing which infor-
mation to provide are the motivations of specific 
groups for using MDMA as well as the perceived 
risks that users associate with its use (35). Known 
desired effects include: sense of relaxed eupho-
ria, decreased inhibition, and elevated mood and 
sociability, as mentioned by Mia. Sexual arousal, 
heightened perceptions, and vivid hallucinations 
can also be desired effects (13). However, desired 
effects can vary according to the phase and the 
years of experience someone has using MDMA. 
Considering the reasons people have to not use 
MDMA or other ATS, and targeting these in pre-
vention messages, can also help to curb or delay 
initiation (36). Often, as was the case for Eva, rea-
sons for not using ATS include the willingness to stay 
in control, mainly related to uncertainties of how 
the effects will work out, and to keep a clear mind. 
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In any phase of use, it is also important to inclu-
de the potential consequences of mixing ATS with 
other drugs. Several ATTUNE participants mentio-
ned poly-drug use to manage their energy and 
counter the effects of ATS; Mia, for instance, star-
ted the party night with MDMA, used cocaine or 
speed to boost her energy, and ended with can-
nabis to help coming down. Warning about the 
effects of mixing substances also includes adverse 
outcomes due to the concomitant use of ATS with 
alcohol (37) (as mentioned by Bob) and energy 
drinks (38). The possibility of engaging in high-risk 
sexual behaviours after taking MDMA should also 
be addressed (39). It is also known that some inti-
mate partners use MDMA to revitalise their con-
nection, and in a few cases this might develop 
into emotionally unhealthy patterns (40). Enga-
ging with the motives of people for using MDMA 
as a relationship “aid”, and helping them to dis-
tinguish forms of emotional harm entangled in a 
couple’s use of it, is recommended.
Other important preventive messages include: 
warning users about potential sleeping and sleep 
deprivation problems; and educating people 
about the potential dangers of hyperthermia, hy-
dration and water intoxication (41, 42). 
Internet-based prevention programmes have also 
shown positive results to reduce the harms of ATS 
use. An online school-based prevention program-
me implemented in secondary schools in Austra-
lia, for example, focused on NPS and MDMA use 
and showed a reduction in  the intent of students 
to use NPS as their knowledge on both MDMA and 
NPS improved (32).
When sharing information, but also when providing 
other interventions, it is important to meaningfully 
involve peers - people with lived experience of ATS 
use and, preferably, part of the same sub-groups 
of ATS users for whom the intervention is planned. 
Several ATTUNE participants mentioned the impor-
tance of peers in influencing their initiation, con-
tinuation and decrease in ATS use. Peer-based 
interventions are a very effective way of sharing 
honest harm reduction education and informati-
on among people who use drugs (43, 44). Peers 
are more effective in engaging with users (45) and 
more easily trusted as they share experiences and 
background. Peer outreach work is particularly ef-
fective for safer drug use education (46).
 
Self-management of drug use
People who use drugs, including those using va-
rious types of ATS, are often able to control their 
drug use to varying levels of success (29, 47, 48). 
Take, for example, the patterns of consumption 
of frequent non-dependent users, such as Mia, or 
non-frequent users, like Tom. Studies have shown 
that self-management of drug use can lead to less 
problematic patterns of use (49) and increase the 
chances of becoming and staying abstinent from 
drugs (50), as was the case for Adam.
While self-management can be learned, it must 
build upon the ability of users, empowering the 
skills and competencies that they already use to 
control their use and reduce their risks (51). Previous 
literature (33) has mapped some of the methods 
already often used by people who use stimulant 
drugs to self-manage their use. They include the 
creation of (informal) rules for use according to 
perceived risk and triggers that include:
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• only using when feeling well;
• using only with friends;
• only use during weekends;
• not using when at work or before work, 
when this is going to negatively impact 
the productivity of the user; and,
• establishing a maximum amount or fre-
quency of use.
 
To be effective, any methods and training in 
self-regulation should be developed together with 
people who use ATS. In these self-management 
processes, peers could also play a supportive role. 
 
Mental health support 
Several people who use ATS do so to cope with 
difficulties and existing mental health problems 
(52, 53). That was the case, for example, for Carl. 
Frequent ATS use may also lead to mental harms 
(6) such as depression, psychotic symptoms (hal-
lucinations) and paranoid thoughts (6, 54). Eviden-
ce shows that frequent and extended use of me-
thamphetamine may cause long-term psychiatric 
and neurological sequels (55). Moreover, chronic 
users have high levels of psychiatric comorbidity 
(such as depression, post-traumatic stress disor-
der (PTSD), ADHD, eating disorders and suicidal 
thoughts/attempts) (7, 56). Mental health support, 
therefore, can be used in initial phases to help 
people cope with stressful life events and prevent 
increased/uncontrolled use (57), or in dependent 
or continued trajectories to help tackle the mental 
harms (partly) due to extended drug use.
 
Drug checking services 
Drug checking services are a harm reduction stra-
tegy usually associated with people using drugs 
in nightlife settings and with less problematic pat-
terns of consumption (58). Nevertheless, these ser-
vices can be useful to reduce the harms of people 
also in continuation and increasing phases of ATS 
consumption.
The illegal status of ATS often leads to unknown 
dosages and contents, increasing the risk of over-
dose as well as of other harms. In this context, 
drug checking can help to detect adulterants in 
substances, thereby decreasing the intent of the 
user to consume potentially dangerous substan-
ces and help inform harm reduction efforts. These 
services can also be crucial for issuing preventa-
tive warnings (in case of dangerous adulterants), 
helping to avoid further harm. Nevertheless, drug 
checking alone might be insufficient, especially 
for less frequent users who may require education 
about adulteration and drug-checking and refer-
ral to support services and drug education that 




The pleasurable effects of “party-drugs” such as 
MDMA may be perceived as compensating the 
unwanted effects caused by use, leading users to 
a low desire to decrease use or to get help (63). 
In that context, interventions that are placed in, 
and adapted to, party settings can be very useful 
to engage ATS users in reducing harms, especially 
users at initial phases of ATS consumption, but also 




Chill-out rooms, for instance, can help MDMA 
users to increase their fluid intake and prevent hy-
perthermia, as well as warning users of the poten-
tial harm of overconsumption of fluids (24). Other 
practices can be promoted at the premises whe-
re party drugs will be consumed. These include 
temperature control at the venue and adequate 
ventilation; adequate provision of free cold water; 
staff training to understand and manage drug-re-
lated risks and emergencies; adequate emergen-
cy provision; and a harm reduction focus for secu-
rity when targeting people in possession of drugs 
for personal use (64).
 
Substitution therapy 
Substitution therapy is an intervention used, in ge-
neral, for a dependent pattern of drug use, such 
as experienced by Bob. Substitution therapy for 
ATS follows a similar rationale as substitution thera-
py for opiates: replacing the use of one drug with 
another based on its perceived safety, level of ad-
dictive potential, effectiveness in relieving symp-
toms, as well as access and level of acceptance 
(65). Whereas opiate drugs, such as methadone 
and buprenorphine, have been widely acknow-
ledged as effective to substitute heroin, there is 
limited evidence of the benefit of pharmacothe-
rapy for reducing ATS use. So far, studies have de-
monstrated only limited benefits for a few drugs, 
such as methylphenidate, bupropion, modafinil, 
and naltrexone (30). 
Despite the low evidence given the lack of studies, 
some also advocate for a “plant-based substitu-
tion” of ATS. Cathinone is the main psychoactive 
ingredient in the leaves of Khat, traditionally che-
wed in the Horn of Africa and Yemen. Some advo-
cate that the plant could be a potential substitute 
for amphetamine given its milder effects (66). In 
practice, some people who use ATS choose to use 
plant-based stimulants that are legal in their coun-
try (such as ephedra, betel, kava, or kratom) in-
stead of using illegal ATS (67). Such a strategy can 
be useful in the earlier phases of ATS use and might 
help both in reducing harms (such as legal risks) 
and the increased consumption of stronger sub-
stances (33). Finally, another much used (self-me-
dication) strategy is to use cannabis to reduce 
cravings and minimise psychological harms such 
as anxiety, aggression and paranoia (‘coming 
down’). While the use of cannabis to ease come-
down is much more widespread for those using 
cocaine and crack cocaine (56, 68), it has also 
been often reported by respondents using MDMA 
in the ATTUNE study (such as by Mia), and in the li-
terature concerning mephedrone users (69). Such 
forms of use of other drugs might be helpful to en-
hance self-regulation.
 
Abstinence-based treatment and  
counselling
For those who are dependent on ATS and/or are 
willing to quit its use, abstinence-based treat-
ment and supportive counselling can be recom-
mended.
A few specific abstinence-based treatments have 
been developed for ATS. An example is the Matrix 
model. This model combines different therapeutic 
interventions and has been proven effective for 
methamphetamine use (70). Specific, structured 
brief counselling has been developed for regu-
lar methamphetamine users that has proven to 
help increase abstinence and manage the risks 
of tobacco smoking, polydrug use, risky injecting 
behaviour, criminal activity, and psychiatric dis-
CCorrelationEuropeanHarm ReductionNetwork
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tress (71) . Brief interventions, such as motivatio-
nal enhancement therapy, have shown to help 
reduce MDMA use and severity of MDMA-related 
problems (72) and promote readiness to chan-
ge (73). In any chosen treatment, follow-up after 
treatment completion is crucial. As in the case of 
Carl, many ATS users repeatedly enrol in drug tre-
atment and, without adequate aftercare, may 
quickly relapse to older habits.
To help people who use ATS to cope with the pro-
cess of abstinence, non-mental health profes-
sionals can also offer counselling for supported 
withdrawal (33). Possible strategies include: pro-
viding oral and written information around the 
withdrawal process (duration, symptoms); helping 
to identify protective and risky factors in previous 
withdrawals; and helping identify key social sup-
ports (74). Finding and focusing on pleasant acti-
vities, and maintaining a healthy diet and routine, 
can also help with strengthening self-regulation 
(12). This strategy was mentioned by ATTUNE par-
ticipants, such as Mia, who set boundaries for use 
and choose specific days to eat healthy, sleep 
early and not to consume. Here again, peers can 
be relevant during the process of abstinence in 
either maintaining abstinence or contributing to 
handle relapse episodes, as happened to Carl in 
his previous attempts to quit.
 
Support in case of acute or  
chronic harms
ATS use may also bring acute or chronic harms. 
ATS use, in general, can cause wakefulness and 
altered attention, an elevated mood and incre-
ased optimism and impulsiveness, as well as re-
duced appetite (11). Despite the fact that these 
might be desired effects for people consuming 
ATS, heavy or chronic consumption can elevate 
such effects to cause unintended harms. Frequent 
MDMA use may cause liver damage and intoxi-
cation (10), besides induced memory impairment 
(20) and sleeping problems as mentioned by de-
pendent users such as Bob. Sleep deprivation can 
cause impaired driving (18) and, in chronic cases, 
amphetamine associated seizures (55). Potenti-
ally life-threatening effects due to MDMA use in-
clude: hyperpyrexia (>40°C), serotonin syndrome, 
hyponatremia (due to overconsumption of fluids) 
and cerebral oedema (75, 76). Lighter ATS effects 
include tachycardia, anxiety, prolonged ‘hang-
over’ or ‘comedown’, as well as bruxism (grinding 
teeth) (24). Bruxism was especially mentioned by 
ATTUNE participants dependent on ATS (speed/
meth), leading to damage and loss of teeth.
While more severe harms need medical care, 
some preventative or supportive interventions can 
be done by non-medical staff. Liver damage and 
toxicity cases require medical and nursing care 
and treatment, but non-medical staff may warn 
users of the possible effects and how to identify 
them on time. Anxiety and agitation may require 
specialised mental health assistance or medicati-
on but interventions such as chill-out rooms, or im-
mediate mental health support, can be done by 
harm reduction workers in a variety of low-thres-
hold settings. In case of elevated temperature, 
simple cooling measures can be applied such as 
use of water and a fan, and applying ice packs to 
the groin and axilla. Non-medical workers can also 
educate recreational users about the potential 




People who use ATS are a very diverse group with 
various and shifting patterns of use. Therefore, not 
all of them will benefit from interventions or sup-
port. The table below presents recommendations 
for people who use ATS, and those providing 
services to them, on how to reduce the harms of 
ATS use in the different trajectories of such use. Gi-
ven the need for multidisciplinary care, a general 
recommendation for service providers is to work 
with partnerships to provide integrated care. 
ATS trajectory Potential support and interventions 
Initial phases • Information about the effects and harms of ATS use
• Peer-led outreach and drug education
• Drug checking services 
• Promote safer social settings 
Continuation • (Peer-led) harm reduction information and counselling 
• Drug checking services
• Mental health support to help people cope with stressful life events 
• Foster self-management and control of drug use
Increase • Mental health support to prevent increased/uncontrolled use
• Skills-building, education and vocational training
• Foster self-management and control of drug use 
• Drug checking services 
• Assistance with basic symptomatic detoxification and withdrawal
Decrease/abstinence • Online support mechanisms and apps to support controlled drug use or 
abstinence 
• Ongoing therapeutic support 
• Skills building, education and vocational training 
• Follow-up support after treatment (continuum of care)
Dependent phase • Harm reduction 
• Services related to social integration, rehabilitation and care (e.g. hous-
ing services, work integration, activation programmes, debt control)
• Family and partner support services
• Specialised, voluntary drug dependence clinical treatment 
• Follow-up support after treatment (continuum of care)
• Mental health support to help tackling problems (related to  drug use)
• Medication assisted withdrawal programmes 
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